Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy?

When considering Invesco's RSPH or iShares' IBB for long-term healthcare investment, two distinct approaches emerge. The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) offers a more diversified, equal-weighted strategy with lower volatility, while the iShares Biotechnology ETF (IBB) provides focused, market-cap-weighted exposure to the biotechnology industry. Both funds have their own merits and cater to different investor preferences.

RSPH invests in 61 healthcare-related companies, with notable positions like Moderna (MRNA), Illumina (ILMN), and Mettler-Toledo International (MTD). This broad-based approach means no single company can significantly impact the fund's performance, making it a more stable option amidst market fluctuations. The fund has a lower expense ratio (0.4%) and a higher yield (0.6%) compared to IBB. It has been tracking the S&P 500 healthcare universe since 2006.

IBB, on the other hand, is more specialized, with 243 holdings: 87% in biotechnology, 9% in life sciences tools and services, and 3% in pharmaceuticals. Its top holdings include Gilead Sciences (GILD), Amgen (AMGN), and Vertex Pharmaceuticals (VRTX). IBB has a higher expense ratio (0.44%) but also offers a higher yield (0.2%). Launched in 2001, IBB has rewarded investors recently, but its performance is more volatile due to the nature of the biotechnology sector.

For investors seeking broad market exposure with lower risk, RSPH may be the better choice. However, those who believe in the continued growth of biotechnology and can tolerate the sector's volatility might prefer IBB. Ultimately, the decision depends on an investor's risk tolerance and confidence in the biotechnology sector's future prospects.